Immuno Cure BioTech

About Immuno Cure BioTech

Immuno Cure BioTech, a clinical-stage biotechnology group, was established in 2015 as a spin-off from the University of Hong Kong's AIDS Institute. Headquartered in the Hong Kong Science Park, the company was co-founded by Percy Cheng, Peter Tang, Andy Wong, Tom Lau, and Dr. Xia JIN. Dr. JIN, who also serves as CEO, brings extensive experience in viral immunology and vaccine development, having held positions at the Shanghai Public Health Clinical Center and the University of Rochester. Tom Lau, the Director of Corporate Finance, contributes a strong background in finance and project management.

The company focuses on the research and development of immunotherapies for cancers and infectious and inflammatory diseases, operating within the biotechnology market. Its business model revolves around advancing its proprietary technology platforms through clinical trials to bring new treatments to market. Immuno Cure has secured significant funding, including a US$12 million tranche of a US$27 million Series A round in July 2023, led by the AEF Greater Bay Area Fund. The company has also been admitted into the Hong Kong Science & Technology Park's Elite Programme, which provides substantial funding to support its growth.

Immuno Cure's core assets are its two patented technology platforms: the "PD-1-enhanced DNA Vaccine Platform" and the "Anti-Δ42PD1 Antibody Platform". The PD-1 platform is designed to develop DNA vaccines that target dendritic cells for a more effective immune response. From this platform, two vaccine candidates are currently in clinical trials: ICVAX, a therapeutic DNA vaccine aiming for a functional cure for HIV/AIDS, and ICCOV, a preventive DNA vaccine for COVID-19. The ICVAX Phase I trial has shown encouraging safety and immunogenicity profiles. The Anti-Δ42PD1 Antibody platform utilizes antibodies targeting a specific protein isoform to restore the function of killer T cells, with potential applications for treating cancers like liver and colorectal cancer. These technologies form the basis of the company's pipeline, which addresses significant unmet needs in global public health.